Creating Value For Our Shareholders

Why Invest in Bayer

Report Highlights

Half-Year Financial Report 2022

Investment Case

Event Highlights

Hands_with_smartphone

Investor Conference Call

Q2 2022 Results

Girl using a drone with the sunset in the background

August 11, 2022

Crop Science Field Technology Showcase

enhancing-transparency

Enhancing Transparency: Bayer’s UN Global Compact adherence Webinar

Investor Conference Call

Q1 2022 Results

Werner Baumann & Norbert Winkeljohann

Virtual Event: Annual Stockholders’ Meeting 2022

womans face with data sheets

Bayer Breakthrough Innovation Forum

Investor Conference Call

FY/Q4 2021 Results

February 18, 2022

Nubeqa Investor Webinar February 2022

VIEW ALL EVENTS

News from Bayer

August 12, 2022

Bayer statement on the decision in the BASF arbitration proceedings

August 11, 2022

Bayer Showcases Leadership in Breakthrough Innovations and Sustainable, Tailored Solutions to Meet Global Challenges in Agriculture

August 08, 2022

Not intended for U.S. and UK Media

U.S. FDA approves additional indication of darolutamide in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC)

Sustainability & Governance

Our Commitment to Sustainability

Discover More Investor Resources

Returning Value to Shareowners

Detailed Insight into Debt & Fixed Income

Business man pointing on rising graph

Discover Our Interactive Stock Charts

CORPORATE GOVERNANCE

Managing and Supervising an Enterprise

CONTACT IR TEAM

Get In Touch With Us

Subscribe To Our Latest Investor News

USES AND SAFETY RECORD

Let’s Talk About Glyphosate

Learn About The Litigation

Glyphosate Litigation Facts